Annotation Detail
Information
- Associated Genes
- KRAS
- Associated Variants
-
KRAS G12/G13
KRAS G12/G13 - Associated Disease
- pancreatic adenocarcinoma
- Source Database
- CIViC Evidence
- Description
- Adding trametinib to gemcitabine does not improve overall survival (OS), progression-free survival (PFS), overall response rate (ORR) or duration of response (DOR) in patients with untreated metastatic adenocarcinoma of the pancreas.
- Variant Origin
- somatic
- Variant Origin
- Somatic
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/622
- Gene URL
- https://civic.genome.wustl.edu/links/genes/30
- Variant URL
- https://civic.genome.wustl.edu/links/variants/77
- Rating
- 4
- Evidence Type
- Predictive
- Disease
- Pancreatic Adenocarcinoma
- Evidence Direction
- Supports
- Drug
- Gemcitabine,Trametinib
- Evidence Level
- B
- Clinical Significance
- Resistance
- Pubmed
- 24915778
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Gemcitabine | Resitance or Non-Reponse | true |
| Trametinib | Resitance or Non-Reponse | true |